Antibacterial Prodrugs to Overcome Bacterial Resistance.

Buthaina Jubeh, Zeinab Breijyeh, Rafik Karaman

Molecules (Basel, Switzerland) 2020 Mar 28

filter terms:

Bacterial resistance to present antibiotics is emerging at a high pace that makes the development of new treatments a must. At the same time, the development of novel antibiotics for resistant bacteria is a slow-paced process. Amid the massive need for new drug treatments to combat resistance, time and effort preserving approaches, like the prodrug approach, are most needed. Prodrugs are pharmacologically inactive entities of active drugs that undergo biotransformation before eliciting their pharmacological effects. A prodrug strategy can be used to revive drugs discarded due to a lack of appropriate pharmacokinetic and drug-like properties, or high host toxicity. A special advantage of the use of the prodrug approach in the era of bacterial resistance is targeting resistant bacteria by developing prodrugs that require bacterium-specific enzymes to release the active drug. In this article, we review the up-to-date implementation of prodrugs to develop medications that are active against drug-resistant bacteria.

Citation

Buthaina Jubeh, Zeinab Breijyeh, Rafik Karaman. Antibacterial Prodrugs to Overcome Bacterial Resistance. Molecules (Basel, Switzerland). 2020 Mar 28;25(7)